Atomwise
John Hamer, who is a managing partner at DCVC Bio. Previously, Dr. Hamer was a Managing Director of Monsanto Growth Ventures and a Managing Director at Burrill & Company. He founded and served as CEO of Arête Therapeutics and was the Chief Scientific Officer and eventually President and CEO of Paradigm Genetics. Earlier, Dr. Hamer was a Professor of Biological Sciences at Purdue University, where he was a David and Lucille Packard Fellow and an NSF Presidential Faculty Fellow.
This person is not in the org chart
This person is not in any offices
Atomwise
4 followers
Atomwise patented the first deep learning technology for structure-based small molecule drug discovery. This AI technology harnesses millions of data points and thousands of protein structures to solve problems that a human chemist would take many lifetimes to solve. They've partnered with some of the world’s largest pharmaceutical and agrochemical companies, and with more than 50 leading academic institutions and hospitals, to tackle the challenges of discovering and developing better drugs and chemicals.